Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases.

ABSTRACT: Over the past decade, Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors have arisen as a novel and promising targeted therapy for breast cancer gene (BRCA)-mutated ovarian and breast cancer patients. Therapies targeting the enzyme, PARP-1, have since established their place as maintenance drugs for cancer. Here, we present existing evidence that implicates PARP-1 as a player in the development and progression of both malignancy and demyelinating disease. These findings, together with the proven clinical efficacy and marketed success of PARP-1 inhibitors in cancer, present the repurposing of these drugs for demyelinating diseases as a desirable therapeutic concept. Indeed, PARP-1 inhibitors are noted to demonstrate neuroprotective effects in demyelinating disorders such as multiple scleros

SUBMITTER: Mekhaeil M 

PROVIDER: S-EPMC8833351 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature